Nutriband Inc. Receives First Order from Fit for Life Group

Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. The Company's development pipeline includes AVERSA Buprenorphine and AVERSA Methylphenidate. The Company is also developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. Its AVERSA Fentanyl is an abuse-deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse-deterrent technology to reduce the abuse and misuse of fentanyl patches. It is also exploring transdermal delivery of proteins and peptides such as exenatide for type 2 diabetes and follicle-stimulating hormone (FSH) for infertility.